YM 900

Drug Profile

YM 900

Alternative Names: YM 90K

Latest Information Update: 27 Nov 2001

Price : $50

At a glance

  • Originator Yamanouchi
  • Class Neuroprotectants
  • Mechanism of Action AMPA receptor antagonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seizures; Stroke

Most Recent Events

  • 27 Nov 2001 Discontinued-I for Seizures in Japan (Injection)
  • 27 Nov 2001 Discontinued-II for Stroke in Japan (Injection)
  • 10 Feb 1999 A preclinical study has been added to the Neurological disorder pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top